Form 8.3 - Pfizer Inc Amendment ...
17 Novembro 2015 - 1:53PM
UK Regulatory
/**/
RNS Number : 0551G
JPMorgan Asset Management
17 November 2015
AMENDMENT
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL
ACT, 1997, TAKEOVER RULES, 2007 (AS AMENDED)
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT
SECURITIES REPRESENTING 1% OR MORE
1.
KEY INFORMATION
|
Name
of person dealing (Note
1)
|
JPMorgan Asset Management
|
|
Company dealt in
|
Pfizer Inc.
|
| Class of relevant
security to which the dealings being disclosed relate
(Note 2) |
Ordinary Shares
|
| Date of
dealing |
13 November 2015
|
2.
INTERESTS AND SHORT POSITIONS
(a)
Interests and short positions (following dealing) in the class of
relevant security dealt in (Note
3)
|
|
Long
|
Short
|
|
|
Number
|
(%)
|
Number
|
(%)
|
|
(1) Relevant securities
|
86,725,728*
|
1.41
|
|
|
|
(2) Derivatives (other than
options)
|
208,388
|
0.00
|
|
|
|
(3) Options and agreements to
purchase/sell
|
|
|
|
|
|
Total
|
86,934,116*
|
1.41
|
|
|
*In addition to the dealings in
section 3, there is an increase in the holding of 2,038 shares due
to a transfer.
(b) Interests and
short positions in relevant securities of the company, other than
the class dealt in (Note 3)
|
Class of relevant
security:
|
Long
|
Short
|
|
|
Number
|
(%)
|
Number
|
(%)
|
|
(1) Relevant securities
|
|
|
|
|
|
(2) Derivatives (other than
options)
|
|
|
|
|
|
(3) Options and agreements to
purchase/sell
|
|
|
|
|
|
Total
|
|
|
|
|
3.
DEALINGS (Note 4)
(a)
Purchases and sales
|
Purchase/sale
|
Number of relevant
securities
|
Price per unit
(USD)
|
|
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Purchase
Sale
Sale
Sale
Sale
Sale
Sale
|
2,450
251
3
51,400
51,447
182
52,610
96,340
144,600
54
730
45
17
122
99
|
33.1776 USD
33.2345 USD
33.2378 USD
33.2573 USD
33.2700 USD
33.2878 USD
33.3411 USD
33.4337 USD
33.4700 USD
33.2190 USD
33.2400 USD
33.2850 USD
33.2890 USD
33.3100 USD
33.3328 USD
|
(b)
Derivatives transactions (other than options transactions)
|
Product name,
e.g. CFD
|
Nature of transaction (Note
6)
|
Number of relevant securities
(Note 7)
|
Price per unit (Note
5)
|
|
|
|
|
|
(c) Options
transactions in respect of existing relevant securities
(i)
Writing, selling, purchasing or varying
|
Product name,
e.g. call option
|
Writing, selling, purchasing,
varying etc.
|
Number of securities to which the option relates
(Note 7)
|
Exercise
price
|
Type, e.g. American, European
etc.
|
Expiry
date
|
Option money
paid/received per unit (Note
5)
|
|
|
|
|
|
|
|
|
(ii)
Exercising
|
Product name, e.g. call
option
|
Number of securities
|
Exercise price per unit (Note
5)
|
|
|
|
|
(d)
Other dealings (including transactions in respect of new
securities) (Note 4)
|
Nature of transaction (Note
8)
|
Details
|
Price per unit (if applicable) (Note 5)
|
|
|
|
|
4.
OTHER INFORMATION
Agreements, arrangements or understandings relating
to options or derivatives
|
Full details of any agreement,
arrangement or understanding between the person disclosing and any
other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to
the voting rights or future acquisition or disposal of any relevant
securities to which any derivative referred to on this form is
referenced. If none, this should be stated.
|
|
|
|
Is a Supplemental Form
8 attached? (Note 9)
|
NO
|
| Date of
disclosure |
17 November 2015
|
| Contact
name |
Evangelos Galiatsatos
|
| Telephone
number |
0207 742 6148
|
|
If a connected EFM, name of
offeree/offeror with which connected
|
N/A
|
| If a connected EFM,
state nature of connection (Note
10) |
N/A
|
The Notes on Form 8.3 can be viewed on the Panel's
website at www.irishtakeoverpanel.ie.
This information is provided by RNS
The company news service from the
London Stock Exchange
END
ISEBRBATMBABBMA
Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
Notícias em tempo-real sobre Pfizer da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Pfizer
